AX-2026-043239

Melanotan II · 10 mg declared · Sangon Biotech (Shanghai) Co., Ltd. · lot SGN-2602-L1809

MARGINALPURITY ONLY

Report ID: AX-2026-043239
Compound: Melanotan II
Compound class: Melanocortin-receptor peptides
Supplier: SGN — Sangon Biotech (Shanghai) Co., Ltd.
Batch / lot: SGN-2602-L1809
Declared label claim: 10mg
Laboratory: Nordanalyt Laboratories
Assay date: 09 Jun 2026
Submitted: 20 Jun 2026
Quarter: 2026-Q2
Submitter: ru.villalobos
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	99.32	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.68	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — linear (open-lactam) precursor (+18 Da)	0.26	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	91.16	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	90.54	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.74	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.724	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	97.2	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	2.40	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.51	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.93	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.25	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.66	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	11.45	min	11.35 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.31	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	58,325	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [L-Phe7]-diastereomer	0.96	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 58,325, and skew follows the reported asymmetry factor of 1.31. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.26 % impurity against a 99.32 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Melanotan II — main peak	11.45	4,827,260	99.32	—
2	linear (open-lactam) precursor (+18 Da)	10.59	12,637	0.26	+18.011
3	oxidised Trp (+16 Da)	11.03	12,637	0.26	+15.995
4	des-acetyl MT-II (−42 Da)	10.89	3,888	0.08	-42.011
5	MT-II dimer (head-to-tail)	14.19	1,944	0.04	+1023.540
6	[L-Phe7]-diastereomer	11.26	1,944	0.04	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	2.40
Counter-ion (acetate)	ion chromatography	5.51
Residual solvent + inorganic residue	estimated	0.93
Total peptide content	by difference	91.16
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.05	99.32	divergence +0.28 pp vs batch median
Total impurities (% area)	not stated	0.68
Largest single impurity (% area)	not stated	0.26
Water (%)	not stated	2.40
Counter-ion (%)	8.9	5.51
Peptide content (%w/w)	87.0	91.16
Endotoxin (EU/mg)	not stated	0.25
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
Assay date: 09 Jun 2026
Submitted to the index: 20 Jun 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot SGN-2602-L1809 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043235	SGN-2602-L1809	Medutest	2026-Q2	99.41	3.06	102.3	Supplier-supplied	1	MARGINAL
AX-2026-043236	SGN-2602-L1809	Janoshik	2026-Q2	98.59	2.31	101.9	Supplier-supplied	0	PASS
AX-2026-043237	SGN-2602-L1809	Janoshik	2026-Q2	98.73	2.19	—	Supplier-supplied	1	MARGINAL
AX-2026-043238	SGN-2602-L1809	Janoshik	2026-Q2	99.01	2.84	99.0	Supplier-supplied	1	MARGINAL
AX-2026-043240	SGN-2602-L1809	PeptideMeter	2026-Q2	98.65	2.87	—	Supplier-supplied	2	MARGINAL
AX-2026-043241	SGN-2602-L1809	PeptideMeter	2026-Q2	98.80	2.57	106.4	Supplier-supplied	2	MARGINAL
AX-2026-043242	SGN-2602-L1809	VendorInvestigate	2026-Q2	98.14	2.18	107.2	Buyer-sourced	1	FAIL
AX-2026-043243	SGN-2602-L1809	PeptideMeter	2026-Q2	98.92	2.81	—	Supplier-supplied	1	MARGINAL
AX-2026-043244	SGN-2602-L1809	Janoshik	2026-Q2	99.24	2.68	98.0	Supplier-supplied	1	MARGINAL
AX-2026-043245	SGN-2602-L1809	Janoshik	2026-Q2	98.54	2.19	100.6	Supplier-supplied	2	MARGINAL
AX-2026-043246	SGN-2602-L1809	Medutest	2026-Q2	98.48	2.62	105.8	Supplier-supplied	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Melanotan II records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042648	GGPeps	GGPE-2603-P8735	Janoshik	2026-Q3	99.10	6.97	—	Supplier-supplied	4	MARGINAL
AX-2026-042479	SWB	SWB-2603-A5707	Janoshik	2026-Q3	99.16	3.67	94.5	Supplier-supplied	1	MARGINAL
AX-2026-042481	SWB	SWB-2603-A5707	Medutest	2026-Q3	98.95	3.37	90.8	Supplier-supplied	1	MARGINAL
AX-2026-042650	GGPeps	GGPE-2603-P8735	Medutest	2026-Q3	99.86	6.49	—	Supplier-supplied	3	MARGINAL
AX-2026-042483	SWB	SWB-2603-A5707	Janoshik	2026-Q3	99.38	3.73	107.2	Supplier-supplied	1	MARGINAL
AX-2026-042651	GGPeps	GGPE-2603-P8735	PeptideMeter	2026-Q3	99.53	7.04	90.7	Supplier-supplied	4	MARGINAL
AX-2026-042478	SWB	SWB-2603-A5707	VendorInvestigate	2026-Q3	98.73	4.34	—	Buyer-sourced	1	MARGINAL
AX-2026-042482	SWB	SWB-2603-A5707	Janoshik	2026-Q3	99.22	4.66	—	Supplier-supplied	1	MARGINAL

Other recent SGN records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043215	Afamelanotide	SGN-2602-Y9898	PeptideMeter	2026-Q3	98.92	3.40	—	Supplier-supplied	1	MARGINAL
AX-2026-043214	Afamelanotide	SGN-2602-Y9898	Janoshik	2026-Q3	99.19	3.41	106.9	Supplier-supplied	1	MARGINAL
AX-2026-043240	Melanotan II	SGN-2602-L1809	PeptideMeter	2026-Q2	98.65	2.87	—	Supplier-supplied	2	MARGINAL
AX-2026-043255	BPC-157	SGN-2512-H1950	Janoshik	2026-Q2	99.06	4.99	—	Supplier-supplied	2	MARGINAL
AX-2026-043242	Melanotan II	SGN-2602-L1809	VendorInvestigate	2026-Q2	98.14	2.18	107.2	Buyer-sourced	1	FAIL
AX-2026-043221	SLU-PP-332	SGN-2602-X9969	Kestrel	2026-Q2	98.70	5.87	—	Supplier-supplied	0	PASS
AX-2026-043245	Melanotan II	SGN-2602-L1809	Janoshik	2026-Q2	98.54	2.19	100.6	Supplier-supplied	2	MARGINAL
AX-2026-043244	Melanotan II	SGN-2602-L1809	Janoshik	2026-Q2	99.24	2.68	98.0	Supplier-supplied	1	MARGINAL